Prostate-Specific Membrane Antigen–Targeted Radioguided Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients with a Suspicion of Locoregional Lymph Node Metastases: The DETECT Trial-Reference-Cited by-同舟云学术

Prostate-Specific Membrane Antigen–Targeted Radioguided Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients with a Suspicion of Locoregional Lymph Node Metastases: The DETECT Trial

Published:2024-01-04 Issue:3 Volume:65 Page:423-429
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Schilham Melline G.M.,Somford Diederik M.,Küsters-Vandevelde Heidi V.N.,Hermsen Rick,van Basten Jean Paul A.,Hoekstra Robert J.,Scheenen Tom W.J.,Gotthardt Martin,Sedelaar J.P. Michiel,Rijpkema Mark

Publisher

Society of Nuclear Medicine

Reference25 articles.

1. Management of patients with node-positive prostate cancer at radical prostatectomy and pelvic lymph node dissection: a systematic review;Marra;Eur Urol Oncol.,2020

2. Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection;Baas;Prostate Cancer Prostatic Dis.,2022

3. More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer

4. Extended versus limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk prostate cancer: early oncological outcomes from a randomized phase 3 trial;Lestingi;Eur Urol.,2021

5. Mapping of Pelvic Lymph Node Metastases in Prostate Cancer

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sterke correlatie tussen de intensiteit van prostaatkankerrecidieven op de PSMA PET/CT-scan en het intra-operatieve gammasonde signaal;Tijdschrift voor Urologie;2024-06-10

2. The DETECT Trial: Are We on the Verge of Precision Surgery in Primary Prostate Cancer?;Journal of Nuclear Medicine;2024-02-15

3. Prostate-specific membrane antigen-targeted surgery in prostate cancer: Accurate identification, real-time diagnosis, and precise resection;Theranostics;2024